146,065 Shares in Organogenesis (NASDAQ:ORGO) Bought by Universal Beteiligungs und Servicegesellschaft mbH

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH acquired 146,065 shares of Organogenesis, valued at approximately $631,000, during the first quarter, holding around 0.12% of the company.
• Organogenesis stock recently opened at $4.51, down 2.4%, with a twelve-month high of $6.71 and low of $2.28.
• Organogenesis reported a loss of ($0.13) earnings per share for the quarter, missing analysts' expectations, and had revenues of $86.69 million, below estimates of $90.77 million.

Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Organogenesis (NASDAQ:ORGO - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 146,065 shares of the company's stock, valued at approximately $631,000. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.12% of Organogenesis at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Victory Capital Management Inc. bought a new stake in Organogenesis during the first quarter valued at about $67,000. CWM LLC increased its position in shares of Organogenesis by 8.9% during the first quarter. CWM LLC now owns 63,894 shares of the company's stock valued at $276,000 after purchasing an additional 5,239 shares during the period. Cerity Partners LLC lifted its position in Organogenesis by 48.2% in the first quarter. Cerity Partners LLC now owns 74,880 shares of the company's stock worth $323,000 after purchasing an additional 24,362 shares during the period. Palumbo Wealth Management LLC increased its holdings in Organogenesis by 91.5% in the 1st quarter. Palumbo Wealth Management LLC now owns 38,666 shares of the company's stock valued at $167,000 after buying an additional 18,476 shares during the period. Finally, Wealth Enhancement Advisory Services LLC raised its stake in shares of Organogenesis by 10.8% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 43,398 shares of the company's stock valued at $187,000 after buying an additional 4,239 shares in the last quarter. 49.57% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently issued reports on ORGO shares. Cantor Fitzgerald reissued an "overweight" rating and issued a $7.00 price target on shares of Organogenesis in a research report on Tuesday, July 15th. BTIG Research reissued a "buy" rating on shares of Organogenesis in a research report on Tuesday, July 15th.

Insider Transactions at Organogenesis

In other Organogenesis news, insider Lori Freedman acquired 142,379 shares of Organogenesis stock in a transaction on Thursday, June 5th. The shares were purchased at an average cost of $2.91 per share, with a total value of $414,322.89. Following the completion of the purchase, the insider owned 837,437 shares in the company, valued at $2,436,941.67. The trade was a 20.48% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have purchased 252,264 shares of company stock valued at $725,732 over the last quarter. 33.00% of the stock is currently owned by company insiders.

Organogenesis Stock Performance

Shares of NASDAQ ORGO traded up $0.09 during mid-day trading on Monday, hitting $4.60. 739,554 shares of the stock were exchanged, compared to its average volume of 1,502,763. The company has a market cap of $583.53 million, a P/E ratio of -27.06 and a beta of 1.76. The stock's fifty day simple moving average is $3.81 and its two-hundred day simple moving average is $4.03. Organogenesis has a twelve month low of $2.28 and a twelve month high of $6.71.

Organogenesis (NASDAQ:ORGO - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.17). Organogenesis had a negative net margin of 3.46% and a negative return on equity of 4.00%. The company had revenue of $86.69 million for the quarter, compared to the consensus estimate of $90.77 million. As a group, equities research analysts predict that Organogenesis will post -0.07 earnings per share for the current fiscal year.

Organogenesis Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.